Allarity Therapeutics, Inc. (ALLR)

NASDAQ: ALLR · IEX Real-Time Price · USD
7.91 -1.08 (-12.01%)
Jan 18, 2022 2:17 PM EST - Market open
Market Cap64.40M
Revenue (ttm)n/a
Net Income (ttm)-9.79M
Shares Out8.08M
EPS (ttm)-1.21
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume125,107
Open8.89
Previous Close8.99
Day's Range7.13 - 8.89
52-Week Range7.13 - 18.20
Beta0.00
Analystsn/a
Price Targetn/a
Earnings Daten/a

About ALLR

Allarity Therapeutics is a clinical stage biopharmaceutical company targeting some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates together with our proprietary DRP® companion diagnostics in a precision medicine approach. We pursue oncology therapeutic candidates that have been “de-risked” through substantiated prior clinical trials by other pharmaceutical companies, demonstrating that these candidates are well tolerated in the tested patient population and have shown promising signs of...

IndustryBiotechnology
Founded2004
CEOSteve R. Carchedi
Employees14
Stock ExchangeNASDAQ
Ticker SymbolALLR
Full Company Profile

Financial Performance

Financial Statements

News

Allarity, Oncoheroes Ink Agreements For Pediatric Cancer Programs

Allarity Therapeutics Inc (NASDAQ: ALLR) and Oncoheroes Biosciences Inc have entered into licensing agreements for Allarity's dovitinib and stenoparib for further clinical development in pediatric cance...

2 weeks ago - Benzinga

Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib...

Oncoheroes will fund and advance the clinical development of both dovitinib and stenoparib in pediatric cancers, utilizing Allarity's DRP® companion diagnostics

2 weeks ago - GlobeNewsWire

What's Happening With Allarity Therapeutics Stock Today?

Allarity Therapeutics Inc (NASDAQ: ALLR) has submitted a marketing application to the FDA seeking approval for dovitinib for the third-line ...

3 weeks ago - Benzinga

Allarity Therapeutics Closes Its Recapitalization, Share Exchange, and $20M PIPE Investment; Lists on U.S. Nasdaq Sto...

llarity Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care...

4 weeks ago - GLOBE NEWSWIRE